Researchers from Florida International University and U.S. Department of Health and Human Services have divulged fused diazepines acting as relaxin receptor 2 (RXFP2; LGR8) agonists.
Nexys Therapeutics Inc. has identified aryl hydrocarbon receptor (AhR) agonists and their prodrugs reported to be useful for the treatment of inflammatory bowel disease, multiple sclerosis and Huntington’s disease.
Astrazeneca AB has synthesized IL-1 receptor-associated kinase 4 (IRAK4) inhibitors reported to be useful for the treatment of cancer, systemic lupus erythematosus, gout, rheumatoid arthritis, psoriasis, Sjögren’s syndrome, myositis and atopic dermatitis, among others.
Current anticoagulant strategies include small-molecule inhibitors and biological entities targeting factor XI (FXI) which, although effective, still have bleeding as a major risk.
As its name suggests, Superluminal Medicines Inc. is aiming for speed. The startup, which closed a $33 million seed round led by RA Capital Management, is combining a biology-focused approach with a generative AI platform it says has the potential to create candidate-ready compounds in a matter of months, with its initial sights set on G protein-coupled receptor targets.
Researchers from Sichuan University synthesized new pyrazole amides based on the previously described NADH-ubiquinone oxidoreductase (complex I, CI) inhibitor IACS-010759. Subsequent optimization resulted in the identification of SCAL-255 and SCAL-266 as lead candidates with potent CI inhibitory activity.
Intron Biotechnology Inc. has entered into an official contract with the U.S. Army Combat Capabilities Development Command (DEVCOM) to develop bacteriophages for combating uropathogenic Escherichia coli (UPEC) infections. DEVCOM, a subcommand of the U.S. Army Futures Command, has been working on a project to develop products that address the risk of urinary tract infections (UTIs) among soldiers exposed to austere environments, such as when deployed or undergoing training.
Intelligent Omics Ltd. has established a target discovery collaboration with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to evaluate novel biological targets for the treatment of hematological cancers.
RSS
